Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 12/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 8/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17104295 | 0.81 | SMN1; SMN2 (0.69) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL4478258 | 0.81 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL14133012 | 0.75 | AURKA (0.61) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL3138079 | 0.73 | MEN1 (0.74) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL8349308 | 0.72 | MEN1 (0.58) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL14665956 | 0.72 | KDR (0.67) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL23293741 | 0.70 | TLR4 (0.61) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL30098485 | 0.70 | TLR4 (0.61) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL8711539 | 0.70 | KMT2A (0.71) | MEN1KMT2ASMN1; SMN2MAPTHTT | |
| SCHEMBL7142315 | 0.70 | KMT2A (0.71) | MEN1KMT2ASMN1; SMN2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503986-B1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS INC (US) | 2015-09-30 | — | — | EP | claimed |
| US-7605164-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2009-10-20 | — | — | US | claimed |
| US-20060173024-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-08-03 | — | — | US | claimed |
| US-7053094-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-05-30 | — | — | US | claimed |
| US-20050148638-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2005-07-07 | — | — | US | claimed |
| US-6908923-B2 | N-(3-oxy-5-functionalphenyl)(hetero)arylcarboxamide derivatives, e.g., 4-fluoro-N-(3-(pyridin-3-yloxy)-phenyl)-benzamide | CYTOKINETICS, INC. (US) | 2005-06-21 | — | — | US | claimed |
| US-20030158233-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | claimed |
| EP-1503986-B1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS INC (US) | 2015-09-30 | — | — | EP | disclosed |
| US-7605164-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20060173024-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-08-03 | — | — | US | disclosed |
| US-7053094-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050148638-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-6908923-B2 | N-(3-oxy-5-functionalphenyl)(hetero)arylcarboxamide derivatives, e.g., 4-fluoro-N-(3-(pyridin-3-yloxy)-phenyl)-benzamide | CYTOKINETICS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20030158233-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158233-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | MEN1 4537/4885KMT2A 2747/4885SMN1; SMN2 633/4885 |
| US-20060173024-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | MEN1 4537/4885KMT2A 2747/4885SMN1; SMN2 633/4885 |
| US-20050148638-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | MEN1 4537/4885KMT2A 2747/4885SMN1; SMN2 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.